Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma

This study is investigating whether using local tumor ablation (destroying tumors using heat or other techniques) to treat a limited number of spread sites (oligometastases) — combined with lenvatinib and a PD-1 inhibitor (immunotherapy) — improves outcomes for patients with advanced liver cancer (hepatocellular carcinoma, or HCC) that has spread to only a few locations. **You may be eligible if...** - You have been diagnosed with primary liver cancer (HCC), confirmed clinically or by biopsy - Cancer spread (metastases) was found within 3 months of your HCC diagnosis - You have no more than 5 metastatic sites, in no more than 2 organs, each no larger than 5 cm - You have already been on lenvatinib plus a PD-1 inhibitor for at least 3 months with controlled liver tumors (partial response or stable disease) - You have also received prior locoregional treatments (such as TACE — a procedure that delivers chemotherapy directly into liver tumors) **You may NOT be eligible if...** - Your liver tumors are not controlled on current therapy - You have more than 5 metastatic sites or more than 2 organs involved - Your metastases are larger than 5 cm - You have not yet received the required prior treatment duration Talk to your doctor to see if this trial is right for you.